Skip to search formSkip to main contentSkip to account menu

MDX-1100

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
JN‐2, a C‐X‐C motif chemokine receptor 3 antagonist, ameliorates arthritis progression in an animal model
2014
2014
Rheumatoid arthritis and the alpha-chemokine IP-10.
Interferon(IFN)-gamma-induced protein 10 (IP-10) and its receptor, CXCR3, appear to contribute to the pathogenesis of rheumatoid… 
Highly Cited
2012
Highly Cited
2012
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in…
OBJECTIVE CXCL10 (also known as interferon-γ-inducible 10-kd protein [IP-10]) is a chemokine that potentially plays a role in the… 
2011
2011
Actualizacion en el tratamiento de la colitis ulcerosa
2010
2010
A Randomized, Placebo-Controlled Trial of MDX-1100, an Anti-IP-10 Antibody, for Moderately to Severely Active Ulcerative Colitis
2008
2008
704 A Phase 1 Open-Label, Single-Dose, Dose-Escalation Study of Mdx-1100, a High-Affinity, Neutralizing, Fully Human Igg1κ Anti-CXCL10 (Ip10) Monoclonal Antibody, in Ulcerative Colitis
2008
2008
T1145 A Double-Blind, Placebo-Controlled, Dose-Escalation, Safety and Pharmacokinetic Study of MDX-1100, a Fully Human Anti-CXCL10 Monoclonal Antibody, in Healthy Subjects
2008
2008
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License